BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
11/10/2021
Initial Lawsuit
01/24/2022
Lawsuit Progression
08/25/2022
Settlement
03/31/2023
This investigation concerns Bumble’s secondary public offering statements about its paying user growth trends, price hike and transition of its payment platform.
11/10/2021
Bumble discloses its Q3 2021 financial results for the quarter ended September 30, 2021, or 17 days after its filed its prospectus for Blackstone to sell up to 20.7 million shares at $54 per share. Bumble discloses 2.866 million average total paying users as of September 30, 2021, up from 2.865 in the previous quarter as reported in the September 13, 2021 prospectus (0.03% increase) or, in the alternative, down from 2.927 million (2.08% decrease) as reported in the Q2 2021 press release filed on August 11, 2021.
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$38.56 | $47.75 | $-9.19 | -19.25% |
This is a securities class action on behalf of all purchasers of the Class A common stock of Bumble directly in Bumble’s secondary public stock offering which took place on or about September 10, 2021.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(a) that Bumble’s paying user growth trends had abruptly reversed in 3Q21 and the company had actually lost tens of thousands of paying users during the quarter;
(b) that paying users had been more reluctant to sign up for the Bumble app during 3Q21 because of the recent price hike for paid services on the app;
(c) that a material number of paying users were leaving the Badoo app and/or could not make payments through the Badoo app due, in substantial part, to problems arising from the company’s transition of its payment platform; and
(d) as a result of the foregoing, Bumble’s business metrics and financial prospects were not as strong as the September 2021 secondary public offering registration statement had represented.
08/25/2022
The court issued an order appointing the lead plaintiff and lead counsel.
10/07/2022
Plaintiffs bring this action as a class action pursuant to Fed. R. Civ. P. 23(a) and 23(b)(3) on behalf of a class consisting of all persons or entities who purchased or otherwise acquired the publicly traded Class A common stock of Bumble directly in or traceable to the Secondary Public Offering (SPO) between September 10, 2021 and January 24, 2022, inclusive, and who were damaged thereby.
Operative complaint
11/18/2022
A motion to dismiss was filed with the court.
On 03/31/2023, lead counsel Bernstein Litowitz Berger & Grossman LLP announced a proposed class action settlement.
The court preliminarily approved the settlement on 04/14/2023. The settlement has a total value of $18,000,000 in Cash.
The notice states that you may be included, if you purchased or otherwise acquired the company’s publicly traded common stock during the period from 09/10/2021 to 01/24/2022, inclusive.
According to the notice, the estimated average cash recovery per damaged share of common stock will be approximately $N/A per share, before deduction of court-approved fees and expenses. Lead Counsel filed a motion for an award of attorneys’ fees not to exceed 25% of the $18,000,000 and payment of expenses not to exceed $200,000.
For information purposes only, last updated on 05/23/2023. Contact the claims administrator or lead counsel for further information.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.